TargetBeta
FGFR4
fibroblast growth factor receptor 4 · also JTK2, CD334, TKF · CD molecules
5 programs in company-led studies act on FGFR4, from 5 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 761 running | FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB | ChEMBL |
| futibatinibrule | Otsuka | phase 3 | 104 running | FGFR1, FGFR2, FGFR3 | ChEMBL |
| infigratinibrule | BridgeBio | phase 3 | 173 running | FGFR1, FGFR2, FGFR3 | ChEMBL |
| irpagratinibrule | Abbisko Cayman | phase 2 | 65 running | – | NCIt |
| BB102rule | Broadenbio | phase 2 | 22 running | – | the studies' text |
Conditions their studies are in
- Carcinoma, Hepatocellular, 2 programs
- Cholangiocarcinoma, 2 programs
- Achondroplasia, 1 program
- Adenocarcinoma Of Esophagus, 1 program
- Biliary Tract Neoplasms, 1 program
- Breast Neoplasms, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Liver Neoplasms, 1 program
- Lung Diseases, Interstitial, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026futibatinib · Otsuka · phase 3 · NCT05727176
- Dec 2026BB102 · Broadenbio · phase 2 · NCT06258408
- Jan 2027infigratinib · BridgeBio · phase 3 · NCT06873035
- Jun 30, 2027irpagratinib · Abbisko Cayman · phase 2 · NCT07327034
- Nov 14, 2028nintedanib · Boehringer Ingelheim · phase 4 · NCT07335562
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.